Related references
Note: Only part of the references are listed.Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs
Yuanyuan Shan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
High-Throughput Virtual Screening, Molecular Dynamics Simulation, and Enzyme Kinetics Identified ZINC84525623 as a Potential Inhibitor of NDM-1
Md Tabish Rehman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
Yi Ru et al.
SCIENTIFIC REPORTS (2016)
Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib
Xiaoyan Pan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Amino Acid Transporters in Cancer and Their Relevance to Glutamine Addiction: Novel Targets for the Design of a New Class of Anticancer Drugs
Yangzom D. Bhutia et al.
CANCER RESEARCH (2015)
Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine
Yuanyuan Shan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker
Xiaoyan Pan et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2015)
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
Yen-Hua Huang et al.
SCIENTIFIC REPORTS (2015)
Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
Christopher A. Eide et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Eupolyphaga sinensis Walker inhibits human chronic myeloid leukemia cell K562 growth by inducing G2-M phase cell cycle arrest and targeting EGFR signaling pathway and in S180 tumor-bearing mice
Bingling Dai et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2014)
Methylene-Bridged Bis(imidazoline)-Derived 2-Oxopyrimidinium Salts as Catalysts for Asymmetric Michael Reactions
Andrey E. Sheshenev et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Design, synthesis and biological activities of Nilotinib derivates as antitumor agents
Xiaoyan Pan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Electrostatic Repulsion and Hydrogen-Bonding Interactions in a Simple N-Aryl-L-valinamide Organocatalyst Control the Stereoselectivity in Asymmetric Aldol Reactions
Yuya Tanimura et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2013)
6-Alkoxy-5-aryl-3-pyridinecarboxamides, a New Series of Bioavailable Cannabinoid Receptor Type 1 (CB1) Antagonists Including Peripherally Selective Compounds
Stephan Roever et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Rhodium(III)-Catalyzed Oxidative Olefination of Pyridines and Quinolines: Multigram-Scale Synthesis of Naphthyridinones
Jun Zhou et al.
ORGANIC LETTERS (2013)
A General Framework for Inhibitor Resistance in Protein Kinases
Deborah Balzano et al.
CHEMISTRY & BIOLOGY (2011)
Enantioselective Organocatalytic Biginelli Reaction: Dependence of the Catalyst on Sterics, Hydrogen Bonding, and Reinforced Chirality
Satyajit Saha et al.
JOURNAL OF ORGANIC CHEMISTRY (2011)
Synthesis of the peptide moiety of the jamaicamides
Ayano Tanaka et al.
TETRAHEDRON LETTERS (2011)
Evaluation of an Antibody-Free ADP Detection Assay: ADP-Glo
Hu Li et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Structure-guided design of C2-symmetric HIV-1 protease enhibitors based on a pyrrolidine scaffold
Andreas Blum et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I:: Looking into the future of controlling drug resistance in chronic myeloid leukemia
Thomas O'Hare et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Sandra W. Cowan-Jacob et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2007)
Unusual sterically controlled regioselective lithiation of 3-bromo-5-(4,4′-dimethyl)oxazolinylpyridine.: Straightforward access to highly substituted nicotinic acid derivatives
Nicolas Robert et al.
ORGANIC LETTERS (2006)
Investigations of branched-chain amino acids and their metabolites in animal models of cancer
VE Baracos et al.
JOURNAL OF NUTRITION (2006)
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
S Kimura et al.
BLOOD (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Protein kinase inhibitors: Insights into drug design from structure
MEM Noble et al.
SCIENCE (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
AS Corbin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Share Paper
